The main question it aims to answer is the correlation between the plasma metabolomic profile of diffuse large B-cell lymphoma and high-grade B lymphomas patients before and after treatment determined by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) and analysed with MetaboAnalyst web platform to identify specific over- or under-expressed markers.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years and older;
Both sexes;
Patients with confirmed histopathological diagnosis of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma;
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;
Patient intending to receive full-dose treatment (Monoclonal antibodies plus anthracycline based combination chemotherapy);
Staged with PET-CT or CT.
You may not be if
Patients with comorbidities that may interfere with the interpretation of the results (CKD in dialysis phase, Autoimmune diseases, uncontrolled Diabetes Mellitus (DM), symptomatic Heart Failure (CHF), HIV positive, positive serology for hepatitis B and C);
Patients requiring multiple blood transfusions (4 or more blood components for the same period or cause);
Pregnant women;
First-line treatment in another institution;
Diffuse transformed Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Clareo Health | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
